OptimizeRx Corp’s recent filing unveils that its Director Lang James Paul acquired Company’s shares for reported $2.44 million on Mar 14 ’25. In the deal valued at $7.60 per share,321,408 shares were bought. As a result of this transaction, Lang James Paul now holds 389,452 shares worth roughly $5.05 million.
Then, FEBBO WILLIAM J bought 20,000 shares, generating $100,220 in total proceeds. Upon buying the shares at $5.01, the CEO now owns 601,253 shares.
RBC Capital Mkts downgraded its OptimizeRx Corp [OPRX] rating to a Sector perform from a an Outperform in a research note published on January 08, 2025; the price target was decreased to $6 from $7. A number of analysts have revised their coverage, including Stephens’s analysts, who began to cover the stock in mid December with a ‘”an Equal-weight”‘ rating. JMP Securities started covering the stock on April 04, 2024. It rated OPRX as “a Mkt outperform”.
Price Performance Review of OPRX
On Tuesday, OptimizeRx Corp [NASDAQ:OPRX] saw its stock jump 2.29% to $12.97. Over the last five days, the stock has lost -5.26%. OptimizeRx Corp shares have risen nearly 30.75% since the year began. Nevertheless, the stocks have risen 166.87% over the past one year. While a 52-week high of $15.71 was reached on 06/12/25, a 52-week low of $3.78 was recorded on 03/11/25.
Levels Of Support And Resistance For OPRX Stock
The 24-hour chart illustrates a support level at 12.50, which if violated will result in even more drops to 12.02. On the upside, there is a resistance level at 13.34. A further resistance level may holdings at 13.70.
How much short interest is there in OptimizeRx Corp?
A steep rise in short interest was recorded in OptimizeRx Corp stocks on 2025-06-13, dropping by 71668.0 shares to a total of 1.57 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-15 was 1.64 million shares. There was a decline of -4.56%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on January 03, 2024 when Barclays began covering the stock and recommended ‘”an Equal weight”‘ rating along with a $15 price target.
